In agreement with the theory that considers the molecular alterations involved in TERT re-expression and telomerase activation as events associated with advanced stage, clinically aggressive carcinomas, in our study, TERT amplification was much more frequent in PTCs with DMs. The gene discussed is TERT; the disease is carcinoma.